New hope: boosting immune system before lung cancer surgery
NCT ID NCT02259621
Summary
This study is testing whether giving immunotherapy drugs before surgery is safe and can help shrink tumors in patients with operable non-small cell lung cancer. It involves 39 participants who will receive one or two immunotherapy drugs, or a combination of immunotherapy and chemotherapy, prior to their planned surgery. The main goals are to check for safety and to see how much the treatment reduces cancer in the removed tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johnathan Spicer
Montreal, Quebec, H4 3J1, Canada
-
Johns Hopkins at Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Swedish Cancer Insitute
Edmonds, Washington, 98026, United States
Conditions
Explore the condition pages connected to this study.